Decipher announces research collaboration with Dendreon to identify genomic drivers of patient response to Sipuleucel-T

This article was originally published here

PROVENGE (sipuleucel-T) was the first U.S. Food and Drug Administration (FDA)-approved immunotherapy made from a patient’s own immune cells. “We are pleased to work with Dendreon on this

The post Decipher announces research collaboration with Dendreon to identify genomic drivers of patient response to Sipuleucel-T appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply